Kane Biotech Inc. has announced that the global animal health company with which it had a Joint Development Agreement (the JDA), previously announced by Kane Biotech on May 13, 2015, has made a business decision to decline its option to commercialize Kane Biotech's companion pet oral care technology. Pursuant to the terms of the JDA and the successful completion of its second milestone trial, Kane Biotech will be paid USD 50,000.

In addition, Kane Biotech has announced that Mr. Grant Humphrey is joining the Corporation as Vice-President Sales, effective July 11, 2016.